NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Ovarian Cancer;Prevention;Rare Diseases;Women's Health Research

PHR: Project Narrative (Project 1) Project 1 aims to apply novel molecular assays to diagnose incidental occult ovarian carcinoma and its precursor lesions in fallopian tubes, the origin of “ovarian” high-grade serous carcinoma. We also propose to assess the most commonly amplified genes in the precursor lesions for their cancer dissemination phenotypes. Our expected results will empower a new diagnostic platform for high-risk women.

PI_NAMEs: PAPADOPOULOS, NICKOLAS  (contact)

PROJECT_TERMS: accurate diagnosis;advanced disease;Age;Algorithms;Aneuploidy;aneuploidy analysis;Biological Assay;Biological Markers;CA-125 Antigen;Cancer cell line;cancer risk;Carcinoma;Carcinoma in Situ;Carcinomatosis;CCNE1 gene;cell motility;Cell Proliferation;child bearing;Classification;Clinical;Clinical Management;cohesion;Detection;Diagnosis;diagnosis standard;diagnostic platform;digital;Discrimination;Disease;DNA;Ectopic Expression;empowerment;Epithelial Cells;Epithelium;Event;exome sequencing;Family history of;fitness;follow-up;Foundations;Future;Gene Amplification;Genetic Predisposition to Disease;genome wide methylation;HBXAP gene;High Risk Woman;Hypermethylation;IGFBP2 gene;Incidence;Individual;innovation;insight;Invaded;Lasers;Lesion;Malignant Epithelial Cell;Malignant neoplasm of ovary;Malignant Neoplasms;Mammalian Oviducts;melting;Meta-Analysis;Methods;methylation biomarker;Microscopic;Molecular;Molecular Diagnosis;Motility;Mucous Membrane;Mutation;Neural Cell Adhesion Molecule L1;novel;novel diagnostics;Oncogenes;Operative Surgical Procedures;Organoids;Ovarian;Ovarian Carcinoma;Ovarian Serous Adenocarcinoma;Ovary;Pathogenesis;Pathologist;Pathology;Patients;Pattern;Performance;Peritoneal;Peritoneum;Phenotype;predict clinical outcome;Procedures;Proliferating;prospective;Proto-Oncogene Proteins c-akt;Publishing;Recommendation;Recurrence;Resolution;Risk;Risk Reduction;Role;routine practice;Salpingo-Oophorectomy;Sampling;Sensitivity and Specificity;Serous;Serum;Signal Transduction;Site;soft tissue;Specificity;Specimen;standard of care;Subgroup;Surface;Testing;Tissues;TP53 gene;transcriptomics;Tubal Excisions;Tube;tumor;tumor initiation;tumorigenesis;Up-Regulation;Update;Validation;Woman

PROJECT_TITLE: Project 1: Diagnose high-grade ovarian serous carcinoma precursors and occult tumors


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Human Genome;Orphan Drug;Ovarian Cancer;Precision Medicine;Rare Diseases;Women's Health Research

ORG_CITY: BALTIMORE

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: JOHNS HOPKINS UNIVERSITY

ORG_STATE: MD

PI_NAMEs: SIMPKINS, FIONA  (contact)

PROJECT_TERMS: Address;alternative treatment;Biological Markers;Blood;brca gene;cancer cell;Cancer Patient;candidate marker;CCNE1 gene;Cell Cycle Progression;Cells;chemotherapy;Clinic;Clinical;Clinical Trials;cohort;Combined Modality Therapy;Data Set;Defect;Development;Diagnosis;DNA biosynthesis;DNA Damage;DNA replication fork;DNA Sequence Alteration;Drug resistance;drug sensitivity;effective therapy;Effectiveness;exome sequencing;Funding;Future;Gene Expression;genetic profiling;Genomics;Hematology;homologous recombination;inhibitor;inhibitor therapy;Investigation;Libraries;Malignant neoplasm of ovary;Measures;Molecular;Molecular Profiling;Monitor;mutant;Mutation;next generation;novel;novel drug combination;novel therapeutics;Organoids;overexpression;patient biomarkers;patient derived xenograft model;patient response;Patient Selection;Patients;Pharmaceutical Preparations;Pharmacotherapy;Phase;phase I trial;Phase II Clinical Trials;Phosphotransferases;Platinum;Poly(ADP-ribose) Polymerase Inhibitor;Pre-Clinical Model;predictive marker;premature;prevent;Proteins;recruit;Research Personnel;Resistance;response;response biomarker;Sampling;Serous;Stress;Testing;Toxic effect;transcriptome sequencing;transcriptomic profiling;transcriptomics;treatment response;treatment strategy;tumor;tumor xenograft;whole genome

PROJECT_TITLE: Project 2: Targeting CCNE1 overexpression in high grade serous ovarian cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 RPRB-H (M1)]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Orphan Drug;Ovarian Cancer;Rare Diseases;Women's Health Research

PHR: PROJECT 3: PROJECT NARRATIVE The proposed research is relevant to public health because it aims to develop novel therapeutic strategies for Type I ovarian cancers including clear cell and endometrioid subtypes which are enriched with loss-of-function ARID1A mutation resulting in reduced DNA repair efficacy and defective cell cycle checkpoint regulation. The proposed research is relevant to the NIH mission to develop fundamental knowledge that will reduce the burden of human illness.

PI_NAMEs: GAILLARD, STEPHANIE  (contact)

PROJECT_TERMS: Activities of Daily Living;Aging;ARID1A gene;arm;base;Base Excision Repairs;biological adaptation to stress;brca gene;cancer cell;Carcinoma;Cell Cycle Checkpoint;Cells;Characteristics;chemotherapy;chromatin remodeling;Clear Cell;Clear cell carcinoma;Clinical;clinical development;clinical efficacy;Collaborations;Combined Modality Therapy;cytotoxic;Data;Defect;Development;DNA;DNA biosynthesis;DNA Double Strand Break;DNA lesion;DNA Methylation;DNA Repair;DNA replication fork;Dose;Double Strand Break Repair;Drug resistance;effective therapy;efficacy evaluation;Endometrial;Endometrioid Carcinoma;Engineering;Enzymes;Epithelial Cells;Excision Repair;Exhibits;Future;Gene Expression;Generations;genotoxicity;Goals;Histology;Human;Impairment;industry partner;inhibitor;Ionizing radiation;Knock-out;Knowledge;Lesion;loss of function;Malignant neoplasm of ovary;Malignant Neoplasms;Mission;Mutate;Mutation;neoplastic cell;Normal tissue morphology;novel therapeutic intervention;novel therapeutics;objective response rate;Oral;Organ;Ovarian;Ovarian Clear Cell Tumor;Ovarian Endometrioid Adenocarcinoma;ovarian neoplasm;Oxidative Stress Induction;Pathway interactions;Patients;personalized therapeutic;Pharmaceutical Preparations;phase 2 study;Phase Ib/II Trial;Phase II Clinical Trials;Poly(ADP-ribose) Polymerase Inhibitor;potency testing;pre-clinical;predictive marker;Predisposition;Proteins;Public Health;Radiation;Recurrence;Regulation;repaired;replication stress;Reporting;Research;Resistance;response biomarker;restraint;Safety;Serous;Site;Small Interfering RNA;Solid Neoplasm;Somatic Mutation;Subgroup;survival outcome;SWI/SNF-Related Gene;temozolomide;Therapeutic;Therapeutic Effect;Toxic effect;TP53 gene;treatment response;tumor;tumor growth;Tumor Promotion;United States National Institutes of Health

PROJECT_TITLE: Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer


NIH_SPENDING_CATS: Biotechnology;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Ovarian Cancer;Rare Diseases;Women's Health Research

PI_NAMEs: FADER, AMANDA NICKLES (contact)

PROJECT_TERMS: 3-Dimensional;algorithm development;Archives;biobank;Biological;Biological Assay;biomarker development;Biostatistics Core;Blood;Cancer Center;Cell Therapy;Cells;Cervical;Clinical;Clinical Protocols;Clinical Trials;Collaborations;Consultations;County Hospitals;Cytology;data management;Data Storage and Retrieval;Databases;Diagnostic;digital imaging;digital pathology;Discipline of obstetrics;Early Detection Research Network;Enrollment;Epithelium;Experimental Designs;experimental study;Gynecologic Oncology;Gynecologic Pathology;Gynecology;Histologic;Hospitals;Human;human tissue;Image Analysis;imaging biomarker;improved;Individual;Infrastructure;Institution;Joints;laser capture microdissection;Lesion;Liquid substance;Logistics;Malignant Female Reproductive System Neoplasm;Malignant neoplasm of ovary;Mammalian Oviducts;Modification;Molecular;molecular pathology;National Research Council;Neoplasms;neoplastic;Oncology;oncology service;Online Systems;Operating Rooms;operation;Organoids;Ovarian;ovarian neoplasm;Ovary;Pathologic;Pathologist;Pathology;Patient Care;Pennsylvania;Process;programs;Proteomics;quantitative imaging;Recommendation;repository;Reproduction spores;Research;Research Personnel;Research Project Grants;Resolution;Resource Sharing;Resources;Safety;Sampling;Services;single cell analysis;Site;software development;Specimen;Study Subject;success;Supervision;Surface;Surgical Oncology;synergism;System;Tissue Banks;Tissue imaging;tissue preparation;tissue processing;Tissue Procurements;tissue reconstruction;Tissue Stains;Tissue Therapy;Tissues;transcriptomics;Translational Research;Tumor Tissue;tumor xenograft;Universities;University Hospitals;Work;World Health Organization

PROJECT_TITLE: Core A: Biorepository Core


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Data Science;Genetics;Human Genome;Networking and Information Technology R&D (NITRD);Ovarian Cancer;Rare Diseases;Women's Health Research

PI_NAMEs: HUANG, PENG  (contact)

PROJECT_TERMS: Adherence;Area;Basic Science;Bioinformatics;Biological;Biometry;Biostatistics Core;Cancer Center;Clinical Sciences;Clinical Trials;Collaborations;Collection;Communities;Computer software;computerized data processing;Consultations;Data;data access;data acquisition;Data Analyses;Data Collection;data dissemination;data infrastructure;data integrity;data management;data preservation;data quality;data sharing;Data Storage and Retrieval;Database Management Systems;Dedications;design;Detection;Development;driving force;empowerment;Ensure;Evaluation;Fostering;frontier;fundamental research;Futility;Future;Genome;genomic data;Genomics;Goals;Good Clinical Practice;Immunologics;in vivo;in vivo evaluation;Information Storage;Infrastructure;Institution;Institutional Review Boards;Malignant neoplasm of ovary;Manuscripts;Measures;member;Methodology;Methods;Mission;Modeling;Monitor;Monitoring Clinical Trials;Morphologic artifacts;multidimensional data;multidisciplinary;Ovarian;Participant;Patients;Pennsylvania;Play;Positioning Attribute;Practice Management;programs;Protocols documentation;public repository;Publications;Quality Control;Recurrence;Research;Research Design;Research Personnel;Resources;Role;Safety;Sampling;Sampling Studies;Secure;Security;software infrastructure;Specialized Program of Research Excellence;Standardization;Technology;Testing;Toxic effect;Translational Research;treatment effect;Universities;Visualization;Writing

PROJECT_TITLE: Core B: Biostatistics Core


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Ovarian Cancer;Rare Diseases;Women's Health Research

PI_NAMEs: WANG, TIAN-LI  (contact)

PROJECT_TERMS: Address;Animals;anti-cancer research;Cancer Etiology;Clinic;Clinical;Collaborations;Communication;Communities;Community Participation;Development;Ensure;Extramural Activities;Feedback;fighting;Fostering;Funding;Goals;high risk;Human Subject Research;improved outcome;innovation;insight;Institution;Malignant neoplasm of ovary;meetings;member;Methodology;Monitor;novel;Ovarian Stimulations;Patient-Focused Outcomes;Pennsylvania;Persons;Pilot Projects;Process;programs;Progress Reports;Protocols documentation;Reagent;Recommendation;Records;Research;Research Design;Research Personnel;Resources;Review Committee;Sampling;Selection Criteria;Teleconferences;The Wistar Institute;Training;Translational Research;Travel;Universities

PROJECT_TITLE: Developmental Research Program


PI_NAMEs: SHIH, IE-MING  (contact)

PROJECT_TERMS: African American;American;anti-cancer research;Award;Cancer Research Project;career;Communities;Competence;Comprehensive Cancer Center;Development;Diagnosis;Disabled Persons;Discipline of obstetrics;Ensure;Etiology;experience;Faculty;Funding;Future;Goals;Grant;Gynecology;Health;improved;India;innovation;Institution;Knowledge;Lead;Malignant neoplasm of ovary;Malignant Neoplasms;Mentors;Mentorship;Minority;minority investigator;next generation;Ovarian;Patients;Peer Review;Pennsylvania;Pharmacologic Substance;Play;Prevention;Problem Solving;Process;Program Development;programs;Progress Reports;Publications;Qualifying;recruit;Research;research and development;Research Personnel;Research Project Grants;Resources;Role;Scholars Program;screening;skills;survivorship;Talents;The Wistar Institute;Time;Training;translational cancer research;Translational Research;translational research program;translational scientist;Underrepresented Minority;Universities;Woman

PROJECT_TITLE: Career Enhancement Program


ADMINISTERING_IC: HD

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Biotechnology;Genetics;Human Genome

ORG_CITY: BAR HARBOR

ORG_NAME: JACKSON LABORATORY

ORG_STATE: ME

PHR: PROJECT NARRATIVE Most human diseases are complex, resulting from interactions between genetic loci. Human and Mammalian Genetics and Genomics: the McKusick Short Course will train a cadre of highly skilled, diverse young scientists on the genetics and genomics of human disease. With a combined focus on medical genetics, mouse genetics and model systems the course will forge a link between basic and clinical research enabling ongoing dialogue and thereby fostering productive clinical outcomes.

PI_NAMEs: ROSENTHAL, NADIA A (contact);VALLE, DAVID

PROGRAM_OFFICER_NAME: STEIN, KATHRYN K

PROJECT_TERMS: Active Learning;Address;Applied Genetics;Basic Science;Bioethics;Bioinformatics;Biological Models;biomedical scientist;career networking;Case Study;Clinical;Clinical Research;Complex;Computational Biology;Disadvantaged;disadvantaged background;Disease;disease model;Education;Educational workshop;Employment;empowerment;Enrollment;Environment;Equilibrium;ethical, legal, and social implication;Ethics;experience;Experimental Genetics;Faculty;forging;Fostering;Funding;Future;Gender;Generations;Genetic;Genetic Databases;Genetic Diseases;Genetic Heterogeneity;Genetic Models;Genetic study;Genetic Variation;genome database;genomic locus;Genomics;Goals;graduate school;graduate student;Grant;health care disparity;Healthcare;Human;human disease;Human Genetics;Hybrids;Immersion;Individual;Inequity;Knowledge;Laboratories;Learning;lectures;Link;Mammalian Genetics;Medical;Medical Ethics;Medical Genetics;Minority;Modeling;mouse genetics;mouse model;National Institute of Child Health and Human Development;next generation;Outcome;Participant;Persons;Play;Population;Postdoctoral Fellow;posters;pre-clinical;Process;Productivity;programs;recruit;Research;Research Personnel;Resources;Role;Sampling;Scholarship;Science;Scientist;skills;Students;Surveys;Techniques;The Jackson Laboratory;Therapeutic Intervention;tool;Training;Underrepresented Populations;Universities;Update;virtual;workforce needs

STUDY_SECTION: CHHD

STUDY_SECTION_NAME: Developmental Biology Study Section[CHHD-C]


ADMINISTERING_IC: GM

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Dementia;Neurodegenerative;Neurosciences;Women's Health Research

ORG_CITY: BELMONT

ORG_NAME: MCLEAN HOSPITAL

ORG_STATE: MA

PHR: Project Narrative Aggression accompanies a number of common human neurodegenerative disorders (e.g. Alzheimer's and other related dementias), with little understanding of how cognitive and aggression symptoms may be linked at the neuronal level. Aggression has been extensively studied in males of many species, but neglected in females (likewise, the interaction of sex and age is neglected). The objective of this research program is to identify the neural circuitry that governs female aggression (K99- mentored phase) and later transition (R00- independent phase) into discovering mechanisms of dementia-related pathology and how these changes affect aggression.

PI_NAMEs: PALAVICINO-MAGGIO, CAROLINE  (contact)

PROGRAM_OFFICER_NAME: SESMA, MICHAEL A

PROJECT_TERMS: Affect;Age;Aggressive behavior;Agitation;Alzheimer's Disease;Amyloid beta-42;Behavioral;Brain;Brain region;Cells;Cognitive;computerized tools;Defect;Dementia;Disease;disease model;Environment;Female;fighting;Genetic;Health;Hospitals;Human;Lead;Learning;Link;male;Maps;medical schools;Mentors;neglect;Nerve Degeneration;neural;neural circuit;Neurodegenerative Disorders;neuronal circuitry;Neurons;novel;overexpression;Pathology;Pathway interactions;Phase;programs;protein aggregation;Reporting;Research;Resources;Rest;sex;Subgroup;Symptoms;System;Systems Biology;therapeutic target;Work

PROJECT_TITLE: Unraveling the neural basis of female aggression and dementia-related aggression: a systems biology approach.


ADMINISTERING_IC: AG

ED_INST_TYPE: SCHOOLS OF MEDICINE

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Dementia;Neurodegenerative;Neurosciences;Sleep Research

ORG_CITY: IOWA CITY

ORG_DEPT: NEUROSCIENCES

ORG_NAME: UNIVERSITY OF IOWA

ORG_STATE: IA

PHR: Project Narrative This diversity supplement to R01 NIA R01AG070841 will provide funding for UI postdoctoral scholar Dr. Louis Kolling to conduct research as part of the parent grant focusing on the etiology of early Alzheimer’s disease. It also provides funding for professional development and travel expenses for the candidate.

PI_NAMEs: MARCINKIEWCZ, CATHERINE ANNE (contact)

PROGRAM_OFFICER_NAME: MACKIEWICZ, MIROSLAW

PROJECT_TERMS: affective disturbance;Alzheimer's Disease;Development;Etiology;Funding;parent grant;Parents;Postdoctoral Fellow;Research;Sleep disturbances;Travel

PROJECT_TITLE: Sleep and affective disturbances in the etiology of Alzheimer's disease


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Clinical Research;Genetics;Pediatric;Primary Immunodeficiencies;Rare Diseases

ORG_CITY: SAN FRANCISCO

ORG_DEPT: PEDIATRICS

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

ORG_STATE: CA

PHR: Project Narrative We propose that the data, materials, and expertise of PIDTC be organized and made available as a resource (the PIDTC Resource) to the entire IEI community (patients, clinicians, researchers, clinical trialists) with key enhancements to expand the utility and quality of the resource, improvements to expand data access and interpretation, and improved dissemination of results to accelerate knowledge generation for the field. We will do this by 1) expanding the PIDTC Resource to increase its utility and improve the power to answer further questions related to the treatment of IEI's including particular genotypes or clinical subtypes of disease; 2) consolidating and building tools and infrastructure to accelerate standardized data collection from ongoing and future studies and trials that are contributing data to the PIDTC Resource; and 3) providing tools to make the PIDTC data more accessible to the broader IEI community including researchers, clinical care providers, patient advocacy groups, patients, foundations, and consortia. The major impact of the proposed resource will be establishment of an organization that facilitates the open use of existing and new data, infrastructure, and study design expertise to expand achievement of evidence-based advances in the treatment of patients with IEI.

PI_NAMEs: DVORAK, CHRISTOPHER CRAIG (contact);HADDAD, ELIE ;MARSH, REBECCA ;TORGERSON, TROY R;WAGNER, MICHAEL

PROGRAM_OFFICER_NAME: MORRIS FEARS, MARGARET A

PROJECT_TERMS: Acceleration;Achievement;Address;Adult;Ally;Autoimmune Diseases;biomedical informatics;Bone Marrow Cell Transplantation;Bone Marrow Transplantation;Canada;care providers;Caring;Case Report Form;Cell Therapy;Cells;Child;Chronic Granulomatous Disease;Clinical;clinical care;clinical research site;clinical subtypes;Collaborations;Communities;community empowerment;congenital immunodeficiency;Data;data access;Data Aggregation;Data Analyses;Data Collection;data exploration;Data Set;data standards;Databases;demographics;Disease;disorder subtype;Educational workshop;Enrollment;Ensure;evidence base;experience;Foundations;Future;gene therapy;Generations;Genes;Genotype;Growth;Health;Immunity;immunodeficiency;Immunologist;Immunology;improved;improved outcome;Inflammatory;Information Dissemination;Infrastructure;International;Knowledge;laboratory equipment;Late Effects;Life;Manuscripts;Mission;Monitor;multi-site trial;Natural History;Observational Study;Outcome;patient advocacy group;Patient Outcomes Assessments;patient population;Patient-Focused Outcomes;Patients;Physicians;podcast;primary immune regulatory disorders;primary outcome;prospective;Recommendation;Recording of previous events;Registries;Research;Research Design;Research Personnel;Research Training;Resources;response;Sampling;Severe Combined Immunodeficiency;single-cell RNA sequencing;Site;social media;Specialist;Standardization;Structure;Survivors;Symptoms;System;T-Lymphocyte;Testing;Therapeutic;Therapeutic Studies;therapy outcome;Time;tool;transplant centers;transplantation therapy;treatment and outcome;treatment planning;virtual;web site;Wiskott-Aldrich Syndrome

PROJECT_TITLE: Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity

STUDY_SECTION_NAME: Special Emphasis Panel[ZAI1 MR-I (M2)]


ORG_DEPT: PATHOLOGY

PHR: Project Narrative The intent of the Cervical Cancer SPORE Program in the next 5 years is to develop novel vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions, and to better reach and protect the next generation of women from oncogenic HPV infection and its sequelae.

PI_NAMEs: HUH, WARNER KING;WU, TZYY-CHOOU  (contact)

PROGRAM_OFFICER_NAME: BASA JANAKIRAM, NAVEENA

PROJECT_TERMS: Acceleration;Address;Adjuvant;Adolescent;Age Years;Alaskan;Antigens;Anus;Bioinformatics;Biometry;black women;Blood;cancer biomarkers;Cancer Etiology;Cancer Patient;cancer therapy;cancer type;career;Cells;Cellular Immunology;cervical cancer prevention;Cervical Cancer Screening;cervical carcinogenesis;Cervical Intraepithelial Neoplasia;Cervix Incompetence;Cervix Uteri;chemoradiation;chronic infection;Clinical;Cold Chains;Communication;Complement;Conization;cost;cost effective;Death Rate;design;Developing Countries;Development;Disease;disenfranchised population;Disparity;Disparity population;DNA;DNA Vaccines;Dose;Dysplasia;Electroporation;Engineering;Epitopes;Exhibits;Female;Formulation;Generations;Genotype;Goals;Head and Neck Cancer;Health Benefit;high risk;Hispanic Women;HIV;HPV screening;HPV-High Risk;Human papilloma virus infection;Human Papilloma Virus Vaccination;Human Papilloma Virus Vaccine;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Human papillomavirus 16;Immunization Programs;Immunocompromised Host;Immunology;Immunosuppression;Improve Access;improved;improved outcome;Incidence;Indigenous;Individual;Infection;Infection prevention;Injections;innovation;intraepithelial;Kidney Transplantation;L2 viral capsid protein;Lesion;Licensing;Licensure;Location;Malignant neoplasm of cervix uteri;Malignant Neoplasms;manufacture;men;Minor;Modality;Native Americans;Needles;next generation;novel;novel therapeutics;novel vaccines;Oncogenic;Organ Transplantation;Pathogenesis;Pathology;Patient-Focused Outcomes;Patients;penis;personalized cancer therapy;Persons;Plasma;population based;premalignant;Premature Birth;Preventative vaccination;Prevention;Preventive;Primary Prevention;Production;programs;prophylactic;psychologic;public health intervention;Recurrence;Refrigeration;Regimen;Research;Residual Neoplasm;Resource-limited setting;rural setting;Safety;scaffold;screening;screening program;Secondary Prevention;Sexually Transmitted Diseases;side effect;standard of care;success;Survival Rate;System;Testing;Therapeutic;therapeutic DNA;Therapeutic Effect;therapeutic HPV vaccinations;therapeutic HPV vaccine;thermostability;Tissues;Training;Treatment Efficacy;Treatment outcome;unvaccinated;Vaccination;vaccine delivery;vaccine development;vaccine formulation;Vaccinee;Vaccines;Vagina;Viral;Virus-like particle;Vulva;Waiting Lists;Woman;women's diagnosis;Women's mortality

PROJECT_TITLE: SPORE in Cervical Cancer


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Patient Safety;Women's Health Research

PI_NAMEs: WU, TZYY-CHOOU  (contact)

PROJECT_TERMS: Administrative Personnel;Adverse event;Advisory Committees;Advocate;Agreement;Annual Reports;Area;Basic Science;Bioinformatics;Biomedical Research;Biometry;career;Clinical Research;Clinical Trials Data Monitoring Committees;Collaborations;Communication;computerized;Consultations;cost;Data;data management;Databases;design;Development;Disparity population;Enrollment;Ensure;Evaluation;Feedback;Freedom;Funding;Human Resources;human subject protection;Human Subject Research;Immunology;Individual;Institution;Intellectual Property;Laboratories;laboratory facility;lectures;Maintenance;Malignant neoplasm of cervix uteri;meetings;Monitor;National Cancer Institute;Nurses;organizational structure;Pathology;Patient Monitoring;patient safety;Patients;Policies;Preparation;Program Research Project Grants;programs;Progress Reports;Property Rights;Publications;quality assurance;recruit;Regulation;Reporting;Research;Research Activity;Research Personnel;Research Project Grants;Resources;Risk;Safety;Specimen;success;symposium;Technology Transfer;Tissues;United States National Institutes of Health

PROJECT_TITLE: Administration/Communication Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HPV and/or Cervical Cancer Vaccines;Immunization;Infectious Diseases;Prevention;Sexually Transmitted Infections;Vaccine Related;Women's Health Research

PHR: Project Narrative Oncogenic human papillomavirus (HPV) infection is a necessary cause of 10% of all cancers of women globally, including 99% of cervical cancers. To help overcome disparities in primary prevention of cervical cancer, here we seek to develop an affordable HPV vaccine that both extends the breadth of protection to cover all cancer- associated HPV types, is stable at ambient temperature and only requires a single administration.

PI_NAMEs: RODEN, RICHARD BRUCE (contact)

PROJECT_TERMS: absorption;Address;Adjuvant;African American;Aluminum Hydroxide;aluminum sulfate;Amino Acids;Animal Model;Antibodies;Antibody Response;Antibody titer measurement;Antigens;atomic layer deposition;Austria;B-Lymphocyte Epitopes;Biological Assay;carcinogenicity;cervical cancer prevention;Cervical Cancer Screening;Chimeric Proteins;Clinical Research;Cold Chains;Country;cross reactivity;Data;Deposition;Developing Countries;Development;Disparity;Dose;Economic Development;Enzyme-Linked Immunosorbent Assay;Epitopes;Fc Receptor;Female;Freeze Drying;Funding;Gardasil;Genetic;Geographic Locations;Glass;Goals;Government;Hispanic Populations;HPV-High Risk;Human papilloma virus infection;Human Papilloma Virus Vaccination;Human Papilloma Virus Vaccine;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Human papillomavirus 16;Human papillomavirus 18;Immune Sera;immunogenic;immunogenicity;improved;In Vitro;Income;innovation;L2 viral capsid protein;Legal patent;Licensing;Location;Logistics;Malignant neoplasm of cervix uteri;Malignant Neoplasms;Mediating;Medical Care Costs;Minor;Monoclonal Antibodies;mouse model;Mucous Membrane;Mus;Nanotechnology;neutralizing antibody;Oncogenic;Oryctolagus cuniculus;Pap smear;particle;Patients;Phagocytosis;phase 1 study;phase I trial;Phylogenetic Analysis;Placebo Control;Population;Positioning Attribute;Primary Prevention;Production;programs;protective efficacy;Proteins;Race;Randomized;Refrigeration;Regimen;response;Safety;scaffold;screening;Serum;Site;Surface;Technology;Temperature;Testing;thermostability;Toxicology;Vaccinated;Vaccination;Vaccine Antigen;Vaccinee;Vaccines;Vagina;virtual;Virus-like particle;volunteer;Woman

PROJECT_TITLE: Thermostable RG-1 VLPs, A Candidate Broadly Protective HPV Vaccine for the Prevention of Cervical Cancer Globally


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HPV and/or Cervical Cancer Vaccines;Immunization;Immunotherapy;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Sexually Transmitted Infections;Vaccine Related;Women's Health Research

PHR: Project Narrative Here, we seek to develop a vaccination regimen that safely and effectively causes the immune system to eliminate otherwise persistent infections of the most dangerous types of human papillomavirus before women develop the precursor lesions of cervical cancer. This approach to cervical cancer prevention may also be effective for other anal, genital and oral cancers caused by these viruses.

PI_NAMEs: HUNG, CHIEN-FU  (contact)

PROJECT_TERMS: 2019-nCoV;Age;Anogenital cancer;antigen-specific T cells;Antigens;Anus;Biopsy;Brazil;Cancer Etiology;CD8-Positive T-Lymphocytes;cell mediated immune response;Cellular Immunity;cellular transduction;Cervical;cervical cancer prevention;Cervical Cancer Screening;cervical carcinogenesis;Cervical Intraepithelial Neoplasia;Cervix Incompetence;Cervix Uteri;chronic infection;Country;Cytology;Dangerousness;Depressed mood;Development;Devices;Disease;DNA;DNA Maintenance;DNA Vaccines;Dose;Double-Blind Method;Excision;Exhibits;FDA approved;Generations;Genitalia;Genotype;Ghana;Goals;Heat-Shock Proteins 70;HPV-High Risk;Human Papilloma Virus Vaccine;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Human papillomavirus 16;Human papillomavirus 18;immune clearance;Immune system;Immunity;Immunization;immunogenicity;Immunotherapy;improved;India;Infection;Injections;Intercept;Intervention;Intramuscular;Intramuscular Injections;Israel;Kenya;Lesion;Licensing;Licensure;Link;link protein;loop electrosurgical excision procedure;malignant mouth neoplasm;Malignant neoplasm of cervix uteri;malignant oropharynx neoplasm;Medical;Molecular;Morbidity - disease rate;mouse model;Mus;Needles;Neoplasms;novel;Oncogenic;Operative Surgical Procedures;Pain;Pathologic;Patients;Pattern;phase 2 study;population based;practical application;Premature Birth;Prevalence;prevent;Prevention;Preventive;Procedures;Proteins;Psychosocial Stress;Qualifying;Randomized;Recommendation;Recurrence;Regimen;Reproduction spores;Resource-limited setting;Risk;routine screening;Safety;safety assessment;screening;screening program;Sexually Transmitted Diseases;side effect;Site;Specimen;subcutaneous;Syringes;T cell response;Testing;Therapeutic;transmission process;Treatment Protocols;tumor;United States;United States Preventative Services Task Force;Vaccination;Vaccine Therapy;Vietnam;viral transmission;Virus;Woman

PROJECT_TITLE: Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HIV/AIDS;HPV and/or Cervical Cancer Vaccines;Immunization;Immunotherapy;Infectious Diseases;Organ Transplantation;Prevention;Sexually Transmitted Infections;Transplantation;Vaccine Related;Women's Health Research

PHR: Project Narrative Human papillomavirus (HPV) type 16 infection causes 50-60% of all cervical cancers (and ~90% of other HPV- associated anogenital and oropharyngeal cancers); HIV co-infection or immunosuppression after organ transplantation increases risk for these cancers. Here we test a candidate therapeutic and preventive vaccine for treatment of HPV16+ cancer precursor lesions in HIV+ and HIV- women, including HIV- patients waiting for a kidney transplant.

PROJECT_TERMS: Acceleration;active control;Animals;Anogenital cancer;Antibodies;Antigen Presentation;Antigen-Presenting Cells;Antigens;Anus;calreticulin;cancer risk;Capsid;CD8-Positive T-Lymphocytes;cell mediated immune response;Cells;Cellular Immunity;cellular transduction;Cervical Intraepithelial Neoplasia;Cervix Incompetence;Cervix Uteri;Clinical;Clinical Data;Clinical Trials;co-infection;cohort;Cross-Priming;Devices;Disease;Disease Outcome;DNA;DNA Vaccines;Dose;Electroporation;Failure;Genotype;Goals;Head and neck structure;Heat shock proteins;HIV;HPV positive;Human papilloma virus infection;Human Papilloma Virus Vaccination;Human Papilloma Virus Vaccine;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Human papillomavirus 16;Humoral Immunities;Immune response;Immunocompromised Host;immunogenicity;Immunologics;Immunosuppression;in vivo;Incidence;Individual;Infection;Injections;Intramuscular;Kidney Transplantation;L2 viral capsid protein;Lesion;Link;Malignant neoplasm of cervix uteri;Malignant Neoplasms;malignant oropharynx neoplasm;Mediating;Methods;Molecular;Mus;Muscle;Needles;neutralizing antibody;open label;Operative Surgical Procedures;organ transplant recipient;Organ Transplantation;Papillomavirus;Pathology;Patients;Pattern;Phase;Physiologic pulse;plasmid DNA;preclinical study;premalignant;Premature Birth;prevent;Preventive;Preventive vaccine;protective effect;Proteins;receptor;Recurrent disease;response;Role;Safety;safety assessment;safety testing;Site;Squamous intraepithelial lesion;System;T cell response;T-Lymphocyte;Testing;Therapeutic;therapeutic candidate;therapeutic HPV vaccine;therapeutic vaccine;Toxic effect;Transplant Recipients;Transplantation;tumor;Vaccination;vaccine immunogenicity;Vagina;vector;Virus;Vulva;Waiting Lists;Woman

PROJECT_TITLE: A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HPV and/or Cervical Cancer Vaccines;Immunization;Immunotherapy;Infectious Diseases;Prevention;Radiation Oncology;Sexually Transmitted Infections;Vaccine Related;Women's Health Research

PHR: Project Narrative The current chemoradiation standard-of-care for inoperable, locally-advanced, stage IIB-IVA cervical cancer has shown limited success. Here, we propose to treat stage IIB-IVA cervical cancer patients with intratumoral vaccination of the therapeutic TA-CIN protein vaccine in conjunction to standard chemoradiation therapy for the secondary prevention of cervical cancer. We will subsequently evaluate intratumoral TA-CIN vaccination with concomitant immune checkpoint blockade therapy in a novel spontaneous cervicovaginal carcinoma model.

PROJECT_TERMS: Adaptive Immune System;Adjuvant;Advanced Development;Affect;Antigen Presentation;Antigens;Antitumor Response;Biological Assay;Biological Markers;Blood;burden of illness;cancer immunotherapy;Cancer Patient;Carcinoma;CD8-Positive T-Lymphocytes;Cell Cycle Kinetics;cell mediated immune response;Cells;Cervical;cervical cancer prevention;cervicovaginal;chemoradiation;Chemotherapy and/or radiation;Cisplatin;Clinical;Clinical Trials;Data;detection method;Developing Countries;Disease;DNA;DNA Vaccines;FDA approved;Foundations;Future;Genome;Genotype;Heat-Shock Proteins 70;high risk;high risk population;Histologic;HPV E7;HPV positive;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Human papillomavirus 16;Human papillomavirus 18;immune checkpoint blockade;Immune response;Immunity;immunogenic;Immunotherapy;improved;improved outcome;Individual;innovation;Innovative Therapy;Intramuscular;Intramuscular Injections;link protein;Malignant neoplasm of cervix uteri;Malignant Neoplasms;Measurement;Measures;Modeling;Molecular;Monitor;Neoplasm Metastasis;neoplastic cell;new technology;Normal Cell;novel;novel therapeutics;Operative Surgical Procedures;Papillomavirus Transforming Protein E6;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phase;Pilot Projects;Plasma;plasmid DNA;potential biomarker;pre-clinical;predictive marker;prevent;Prevention;Proteins;Radiation therapy;Recurrence;Recurrent disease;Refractory;Regimen;Residual Neoplasm;Residual state;Route;Safety;safety and feasibility;safety assessment;screening;Secondary Immunization;Secondary Prevention;Skin;specific biomarkers;standard care;standard of care;success;Survival Rate;T cell response;T-Lymphocyte;Testing;Therapeutic;therapeutic HPV vaccine;tumor;Vaccination;Vaccine Therapy;Vaccines;Vaccinia;Vaccinia virus;Woman

PROJECT_TITLE: Therapeutic HPV vaccines (PVX7) for Advanced Cervical Cancer


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HIV/AIDS;Women's Health Research

PI_NAMEs: WANG, HAO  (contact)

PROJECT_TERMS: Address;Alabama;Bioinformatics;Biological Assay;Biological Markers;Biometry;career;career development;Clinical Trials;Collaborations;Colorado;Consultations;Data;Data Analyses;Data Collection;data management;data sharing;Data Storage and Retrieval;Database Management Systems;design;Development;Ensure;experience;Experimental Designs;Generations;Goals;Human Papillomavirus;Human Resources;Immunology;Infrastructure;innovation;Malignant neoplasm of cervix uteri;Medical;meetings;member;Methodology;Methods;Modeling;Molecular;novel;operation;Pathology;Positioning Attribute;preclinical study;Process;Program Development;programs;Protocols documentation;Publications;Quality Control;Regulation;Research;research clinical testing;Research Methodology;Research Personnel;Research Project Grants;Research Support;Resources;Science;Services;Specialist;Specific qualifier value;Specimen;Statistical Data Interpretation;statistical service;synergism;Techniques;Testing;Tissues;Translational Research;United States National Institutes of Health;Universities;Validation;Visualization;Work

PROJECT_TITLE: Biostatistics/Bioinformatics Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HIV/AIDS;HPV and/or Cervical Cancer Vaccines;Immunization;Infectious Diseases;Prevention;Sexually Transmitted Infections;Vaccine Related;Women's Health Research

PI_NAMEs: VISCIDI, RAPHAEL PAUL (contact)

PROJECT_TERMS: Alabama;Antigens;biobank;Bioinformatics;Biological;Biological Assay;Biometry;Blinded;Blood;Blood Banks;Blood specimen;Carcinoma;career;career development;Clinical;Clinical Protocols;Clinical Trials;clinically relevant;Colorado;Consultations;Country;data integrity;data management;Data Set;Databases;Development;digital;digital imaging;Disasters;Disease;Doctor of Medicine;Doctor of Philosophy;Dysplasia;encryption;Enrollment;Ensure;Epidemiology;Funding;Generations;Genotype;Goals;Guidelines;Gynecologic;Gynecology;Harvest;Histologic;Human;Human Papilloma Virus Vaccine;Human Papillomavirus;Human Resources;human tissue;Image Analysis;image processing;Immune response;Immunologics;Immunology;In Situ;Institution;laser capture microdissection;Lesion;Liquid substance;Malignant neoplasm of cervix uteri;Medical;member;Microdissection;Microscopic;Molecular;National Cancer Institute;National Research Council;neoplastic;Normal tissue morphology;Online Systems;participant enrollment;Pathologic;Pathologist;Pathology;Patient Care;Peripheral Blood Mononuclear Cell;Photography;Practice Guidelines;preservation;Process;programs;Protocols documentation;Recommendation;Recovery;recruit;Reproducibility;Research;Research Design;Research Personnel;Research Project Grants;Resource Sharing;Resources;Sampling;Serology test;Serum;Site;Specimen;success;System;T-Lymphocyte;Technology;Tissue Banks;Tissue Microarray;tissue preparation;Tissue Sample;Tissue Stains;Tissues;Translational Research;tumor;Universities;Vaccination;Validation;web platform;Work;World Health Organization

PROJECT_TITLE: Tissue/Pathology/Immunology Core


PROJECT_TERMS: Advertising;Alabama;anti-cancer research;Award;Cancer Biology;Collaborations;Colorado;Communication;Community Participation;Comprehensive Cancer Center;design;Development;Ensure;fighting;Funding;high risk;Immunology;Infrastructure;innovation;Malignant neoplasm of cervix uteri;Malignant Neoplasms;medical schools;meetings;Methodology;Molecular Biology;Molecular Genetics;novel;Pilot Projects;programs;Qualifying;Radiology Specialty;Recommendation;Research;Research Personnel;Research Project Grants;Resources;Rotation;success;Testing;Translational Research;United States National Institutes of Health;Universities


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Racial and Ethnic Minority Health Research;Women's Health Research

PROJECT_TERMS: Address;Agreement;Alabama;Award;Basic Science;career;catalyst;Collaborations;Communication;Community Participation;Comprehensive Cancer Center;Creativeness;Disabled Persons;Disadvantaged;Disparity population;early-career faculty;Epidemiologist;ethnic minority;Ethnic Population;Faculty;Funding;Goals;improved;Individual;innovation;Malignant neoplasm of cervix uteri;meetings;member;Mentors;Mentorship;Minority;Minority Recruitment;Patient-Focused Outcomes;Process;programs;Progress Reports;Qualifying;racial minority;racial population;Recommendation;recruit;Research;Research Personnel;Research Project Grants;Scientist;Talents;Translational Research;translational scientist;Underrepresented Populations;Universities;Veterans;Woman


ORG_CITY: WOODS HOLE

ORG_NAME: MARINE BIOLOGICAL LABORATORY

PHR: Project Narrative In its nearly 130 years of existence, the six-week intensive lecture- and laboratory-based Embryology course has played a pivotal role in training generations of Developmental Biologists. These individuals and their students, in turn, have been at the center stage of the biomedical sciences, as evidenced by the fact that developmental biologists have: 1) provided mechanistic understanding of fundamental biological processes (e.g., pattern formation, organogenesis, tissue polarity, epigenetics, aging, cell death); 2) discovered morphogens, microRNAs, and defined the major signaling pathways used by cells to communicate with each other; and 3) have provided the foundations for stem cell biology, tissue engineering and the context to understand human birth defects and disease. Developmental Biology continues to expand into new areas of research such as regeneration, stem cells, systems biology and growth control. By teaching the next generation of developmental biologists, the Embryology course aims to continue spurring and promoting a long-standing tradition of helping transform the biomedical sciences at large.

PI_NAMEs: HYMAN, LINDA E (contact);PIOTROWSKI, TATJANA ;WIKRAMANAYAKE, ATHULA H

PROGRAM_OFFICER_NAME: MUKHOPADHYAY, MAHUA

PROJECT_TERMS: 3-Dimensional;Ablation;Academia;Acceleration;Adult;Aging;American;Animal Model;Animals;Area;Arthropods;ascidian;Behavior;Biological;Biological Models;Biological Process;Biology;biophysical techniques;broadening participation research;Caenorhabditis elegans;career;Cell Death;Cell Lineage;Cells;Cephalopoda;Chick;Chickens;Child Health;Cnidaria;Collaborations;Collection;Communication;Communities;comparative;confocal imaging;Congenital Abnormality;course introduction;CRISPR/Cas technology;Crustacea;Ctenophora;design;Development;Developmental Biology;Disease;Doctor of Philosophy;doctoral student;Drosophila genus;early-career faculty;Echinodermata;Education;educational atmosphere;Educational Curriculum;Educational process of instructing;egg;Electroporation;Embryo;Embryology;Environment;Epigenetic Process;Equipment;Evolution;experience;experimental study;Exposure to;Faculty;Faculty Recruitment;field study;Foundations;Generations;Genetic;Genomics;graduate student;Growth;Health;hemichordate;Hour;Human;Human Development;Imaging technology;Individual;insight;instructor;instrumentation;International;Invertebrates;Laboratories;laboratory experiment;Laboratory Research;Larva;Lead;Leadership;Learning;lecturer;lectures;Libraries;Light;marine;Marine Invertebrates;medical schools;Mentors;Mentorship;Methodology;Methods;MicroRNAs;Microscope;Microscopy;Modeling;Modernization;Molecular;Molecular Genetics;morphogens;Mus;Natural regeneration;Nematoda;new technology;next generation;Operative Surgical Procedures;Organism;Organogenesis;Participant;Pattern Formation;Planarians;Play;Positioning Attribute;Postdoctoral Fellow;pre-doctoral;Process;Rana;Reagent;Recording of previous events;Recruitment Activity;regenerative biology;Reporter;Research;Research Institute;Research Personnel;RNA Interference;Role;Science;Scientist;Sea Urchins;senior faculty;Series;Signal Pathway;stem cell biology;stem cells;Student Selections;student training;Students;superresolution microscopy;System;Systems Biology;Talents;teaching assistant;Techniques;Technology;Time;Tissue Engineering;Tissue Grafts;Tissues;tool;Training;Underrepresented Populations;Universities;Urochordata;Vendor;Zebrafish

PROJECT_TITLE: Embryology: Methods & Concepts in Modern Developmental Biology


ADMINISTERING_IC: HL

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

ORG_CITY: DAVIS

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF CALIFORNIA AT DAVIS

PHR: PROJECT NARRATIVE The UC Davis T32 in Comparative Lung Biology and Medicine prepares predoctoral and postdoctoral trainees during a critical and formative period in their research careers. The program aims to train the next generation of scientists through interdisciplinary research and coursework that address issues of direct relevance to the NHLBI mission. Our faculty and trainees foster a creative training and scientific milieu that facilitates their development into independent investigators in academic and government research careers.

PI_NAMEs: GONCHAROVA, ELENA ;KENYON, NICHOLAS J. (contact)

PROGRAM_OFFICER_NAME: ESPINOZA-PINTUCCI, MARISOL

PROJECT_TITLE: Training in Comparative Lung Biology and Medicine

STUDY_SECTION: NITM

STUDY_SECTION_NAME: NHLBI Institutional Training Mechanism Study Section[NITM (JA)]


ORG_CITY: CHAPEL HILL

ORG_DEPT: GENETICS

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

ORG_STATE: NC

PHR: Overall - Narrative The UNC Breast Cancer SPORE submits its revised Year 30- 34 competitive renewal based upon substantial productivity and impact, particularly in the areas of disparities, genomics and translation as well as remarkable CEP success with recruitment of 17 new faculty 8 of whom are URIM and 12 of whom are women. Continued evolution, innovation and institutional commitment mark the 2 continuing and 2 new projects, all linked by the theme of immune analysis and therapeutic intervention in triple negative breast cancer. The renewal includes the 30th anniversary of the SPORE funded Carolina Breast Cancer Study and the launch of Phase 4 (3000 new cases, 50% Black, 50% younger), with biospecimens, social determinants of health and clinical data in this new era of breast cancer therapy.

PI_NAMEs: CAREY, LISA A;PEROU, CHARLES M (contact)

PROJECT_TERMS: Address;Adherence;Advocate;Africa South of the Sahara;Age;Age disparity;age effect;aged;Anniversary;Antineoplastic Agents;Area;Basic Science;Behavioral;Biological;biological heterogeneity;Biological Markers;Black race;black women;Breast Cancer Patient;Breast Cancer therapy;Cancer Biology;cancer health disparity;CAR T cell therapy;care delivery;career;career development;Career Mobility;Caring;Cell Therapy;Cells;chemotherapy;chimeric antigen receptor T cells;Clinical;Clinical Data;Clinical Sciences;Collaborations;Combination immunotherapy;Communication;Communities;community engagement;Complex;Consent;Data;design;Development;Diagnostic;disease heterogeneity;Disparity;Doctor of Philosophy;efficacy evaluation;Encapsulated;Endogenous Retroviruses;Engineering;epidemiologic data;Ethnic Origin;Evolution;Faculty;first-in-human;follow-up;Foundations;Funding;Generations;Genomics;Goals;health care availability;health data;health difference;Health Services Research;Heterogeneity;Immune;Immune response;Immune system;Immunologist;Immunotherapeutic agent;Immunotherapy;Individual;Infrastructure;innovation;Institution;International;Intervention;Investments;Link;Longevity;low socioeconomic status;Malignant Breast Neoplasm;Medicaid;Medicine;Mentors;Metastatic breast cancer;Methods;minority disparity;Minority Groups;Minority Health Research;Modeling;neoantigens;new technology;new therapeutic target;next generation;North Carolina;novel;novel marker;novel therapeutic intervention;novel therapeutics;Outcome;Paper;Patient Outcomes Assessments;patient population;Patient-Focused Outcomes;Patients;Phase;phase 1 study;phase 3 study;phase 4 study;Population;population based;Population Research;Population Sciences;Population Study;predicting response;predictive marker;Process;Productivity;prognosis biomarker;programs;Publications;Publishing;Race;racial disparity;Radiation Induced DNA Damage;recruit;Research;Research Personnel;Resistance;resistance mechanism;response;Rural Population;Sampling;Seminal;Series;social determinants;Social Environment;social health determinants;Societies;study population;success;System;Technology;Testing;The Cancer Genome Atlas;Therapeutic;Therapeutic Intervention;therapy resistant;Toxic effect;translational goal;Translational Research;translational scientist;Translations;triple-negative invasive breast carcinoma;tumor;Tumor Biology;tumor-immune system interactions;Urban Population;Woman;young woman

PROJECT_TITLE: SPORE in Breast Cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 RPRB-6 (M1)]


NIH_SPENDING_CATS: Aging;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Women's Health Research

PI_NAMEs: PEROU, CHARLES M (contact)

PROJECT_TERMS: Achievement;Address;Advocate;anti-cancer research;Breast;Budgets;Cancer Center;cancer clinical trial;career;career development;chimeric antigen receptor T cells;Collaborations;community engagement;Community Outreach;Comprehensive Cancer Center;Data;Development;Disparity;Elderly;Elements;Evaluation;Faculty;Funding;Genomics;Hematology;Historically Black Colleges and Universities;Immune system;Individual;Infrastructure;Institution;Intellectual Property;International;Leadership;Malignant Breast Neoplasm;medical schools;Medicine;meetings;Mentors;Mentorship;Monitor;new technology;Occupational activity of managing finances;Oncology;Patients;Pilot Projects;Population Sciences;Process;Prognosis;Program Research Project Grants;programs;Progress Reports;Protocols documentation;recruit;Reporting;Research;Research Personnel;Resistance;Resources;Role;Schedule;Sister;skills;System;Talents;technology development;Therapeutic;translational model;Translational Research;translational scientist;UNC Lineberger Comprehensive Cancer Center;Universities

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Aging;Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Precision Medicine;Racial and Ethnic Minority Health Research;Social Determinants of Health;Women's Health Research

PHR: Project 1: Carolina Breast Cancer Study (CBCS): Linking Tumor Biology to Social - Narrative Black women experience different breast cancer outcomes, with tumor biology, individual exposures, community-level, and structural determinants playing simultaneous roles; effective interventions must be integrative, addressing multi-level determinants in a holistic model. This proposal will evaluate tumor biology in context of a multi-level cells-to-society model to identify predictors of recurrence and survival and to identify novel interventions relevant to precision management of breast cancer.

PI_NAMEs: TROESTER, MELISSA A. (contact)

PROJECT_TERMS: Address;Advocate;Age;age acceleration;aging related disease;Biological;black women;breast cancer progression;breast cancer survival;Breast Cancer survivor;cancer recurrence;cancer survival;Cardiovascular Diseases;Cells;Cessation of life;Chronic Disease;Clinical;cohort;Communicable Diseases;Communities;community engagement;community-level factor;comorbidity;Coronavirus;Data;data integration;data visualization;Diabetes Mellitus;differential expression;Disadvantaged;Disease;Disparity;diverse data;DNA Repair;early onset;Education;effective intervention;Epidemic;ERBB2 gene;Estrogen receptor negative;Estrogen receptor positive;experience;Exposure to;Frequencies;Genomics;Goals;Health;health equity;health inequalities;Health Services Accessibility;High Prevalence;high risk;Immune response;Immunologics;Income;Individual;inequitable distribution;Inequity;innovation;Intervention;Joints;Lead;Link;Malignant Breast Neoplasm;Measures;Modeling;Molecular;mortality;mortality disparity;mutational status;neighborhood disadvantage;novel;Obesity;Outcome;outcome disparities;Participant;Patients;personalized management;Phase;phase 3 study;Play;precision medicine;premature;Proliferating;Quality of life;Race;racial difference;racial discrimination;racial disparity;racism;Recurrence;Recurrence Score;Research;Resources;Risk;Role;Sample Size;Sampling;Severities;social;social deprivation;social determinants;Social Environment;social influence;Societies;structural determinants;Structural Racism;study population;survivorship;syndemic;The Cancer Genome Atlas;tool;TP53 gene;treatment pattern;treatment response;tumor;Tumor Biology;tumor microenvironment;Tumor Tissue;United States;Variant;young woman

PROJECT_TITLE: Project 1: Carolina Breast Cancer Study


NIH_SPENDING_CATS: Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Immunization;Immunotherapy;Precision Medicine;Radiation Oncology;Vaccine Related;Women's Health Research

PHR: Project 2: Determinants of Response and Resistance to DNA-Damaging Radiation Plus Immunotherapy Combinations in Triple Negative Breast Cancer – PROJECT NARRATIVE Immune checkpoint inhibition (ICI) combined with chemotherapy has transformed outcomes for patients with early-stage triple negative breast cancer (TNBC). Breast SPORE Project 2 will identify biomarkers that can inform the optimal use of new combinations of ICI with targeted radiation therapy and/or neoantigen vaccination in early stage TNBC.

PI_NAMEs: GUPTA, GAORAV P. (contact)

PROJECT_TERMS: Abscopal effect;adaptive immunity;Aftercare;anti-PD-1;anti-PD1 therapy;anti-tumor immune response;Antibody Response;B-Lymphocytes;Bioinformatics;Biological Assay;Biological Markers;biomarker identification;Biopsy;Blood specimen;Breast;Breast biopsy;CD8-Positive T-Lymphocytes;checkpoint inhibition;chemotherapeutic agent;chemotherapy;Clinical;Clinical Trials;Combination immunotherapy;Combined Modality Therapy;Coupled;CXCL9 gene;cytotoxic;Cytotoxic Chemotherapy;Data;Dendritic Cells;Disease-Free Survival;Disseminated Malignant Neoplasm;DNA Damage;Dose;efficacy evaluation;exhaustion;Future;Gene Expression Profile;genetic signature;Genetically Engineered Mouse;Goals;Human;Immune checkpoint inhibitor;Immune response;Immuno-Chemotherapy;Immunogenomics;Immunologic Stimulation;Immunotherapy;Impairment;improved;In complete remission;Localized Malignant Neoplasm;lymph nodes;Malignant Breast Neoplasm;Measures;Metastatic Neoplasm to Lymph Nodes;mouse model;neoantigen vaccination;neoantigens;Neoplasm Metastasis;Newly Diagnosed;novel therapeutics;Outcome;overtreatment;Pathologic;Pathway interactions;Patient-Focused Outcomes;Patients;pembrolizumab;personalized medicine;personalized therapeutic;Phase I Clinical Trials;pre-clinical;Pre-Clinical Model;predictive marker;Primary Neoplasm;programmed cell death protein 1;Radiation Induced DNA Damage;Radiation therapy;Radioimmunotherapy;randomized trial;recruit;Regimen;Research Personnel;Resistance;response;response biomarker;Role;Safety;side effect;standard of care;Statistical Data Interpretation;synergism;T cell response;T-Lymphocyte;Testing;Therapeutic;therapy resistant;Toxic effect;transcriptomics;Treatment Efficacy;Treatment-related toxicity;triple-negative invasive breast carcinoma;tumor;Tumor Immunity;tumor microenvironment;Tumor-associated macrophages


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Human Genome;Immunotherapy;Precision Medicine;Women's Health Research

PHR: Project 3: Development of Novel Therapies and Biomarkers for TNBC Patients - Narrative In recent years new therapies targeting and activating the immune system to attack TNBC tumor cells have become a standard of care. This proposal seeks to improve the effectiveness of these immune system activating therapies by testing new drugs, and new combinations, that activate multiple components of the immune system. In addition, we have also determined that many TNBC have a unique tumor cell metabolism and here we are performing experiments to target this characteristic, and exploring combinations of these metabolism and immune drugs, to improve survival outcomes for patients with TNBC.

PROJECT_TERMS: Adjuvant Therapy;Agonist;Anabolism;Anti-CD40;anti-CTLA4;anti-PD-1;anti-PD-L1;Antibodies;B-Lymphocytes;Biological;Biological Markers;Biology;biomarker validation;Cell Communication;Cell Compartmentation;Cell Physiology;Cells;Characteristics;chemotherapy;Clinical;Clinical Treatment;Clinical Trials;co-clinical trial;Collaborations;combinatorial;Combined Modality Therapy;Data;Dendritic Cells;Dependence;Development;Dihydroorotate dehydrogenase;Dihydroorotate Dehydrogenase Inhibitor;Drug Targeting;Early treatment;Effectiveness;efficacy evaluation;efficacy testing;Epithelial Cells;ERBB2 gene;Estrogen receptor negative;Estrogen Receptors;Evaluation;experimental study;Foundations;Future;Gene Expression Profile;Genetic;Genetically Engineered Mouse;genomic biomarker;genomic profiling;genomic signature;Genomics;Glutamine;Goals;Heterogeneity;Histology;Human;Image;imaging biomarker;Immune;immune cell infiltrate;Immune checkpoint inhibitor;Immune system;Immune Targeting;Immunologic Markers;immunological diversity;Immunotherapeutic agent;Immunotherapy;immunotherapy clinical trials;improved;In Vitro;in vitro testing;in vivo;inhibitor;kinase inhibitor;Learning;Leflunomide;Liposomal Doxorubicin;Macrophage;Malignant Breast Neoplasm;Malignant Neoplasms;Medical center;Mesenchymal;Metabolic;Metabolism;mouse model;Mus;nano-string;Neoadjuvant Therapy;neoplastic cell;new therapeutic target;novel;novel marker;novel therapeutics;nucleotide metabolism;outcome prediction;Patient Selection;Patient-Focused Outcomes;Patients;pembrolizumab;Pharmaceutical Preparations;Phenotype;potential biomarker;predicting response;Prediction of Response to Therapy;predictive marker;Predictive Value;progesterone receptor negative;Progesterone Receptors;Prognosis;prognostic;programmed cell death ligand 1;Progression-Free Survivals;Proliferating;PTEN gene;Pyrimidine;Pyrimidine Nucleotides;Recurrence;Regimen;Resistance;response;response biomarker;Role;single cell genomics;single-cell RNA sequencing;Solid Neoplasm;Specimen;standard of care;Study models;survival outcome;synergism;T-Lymphocyte;Testing;Therapeutic;therapeutic target;therapeutically effective;TNFRSF5 gene;TNFSF5 gene;transcriptome sequencing;transcriptomics;treatment arm;Treatment Efficacy;treatment response;triple-negative invasive breast carcinoma;tumor;tumor heterogeneity;tumor metabolism;Tumor Subtype;Variant;Vertebral column


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Immunotherapy;Neurosciences;Orphan Drug;Rare Diseases;Women's Health Research

PHR: Project 4: Activity of CAR T cell Therapy for Patients with Metastatic TNBC - Narrative We have had success in treating patients with hematological malignancies by using their own immune cells modified with a chimeric molecule that eliminates tumor cells but spare part of the immune B-lymphocytes. In this project we intend to conduct a Phase I clinical trial to test safety and antitumor activity of a novel chimeric antigen receptor in patients with triple negative breast cancer (TNBC). Furthermore, we will implement novel approaches to enhance our capacity to generate more functional T cells for adoptive T cells therapy.

PI_NAMEs: DOTTI, GIANPIETRO  (contact)

PROJECT_TERMS: Adoptive Transfer;Antigens;antitumor effect;Autologous;B lymphoid malignancy;B-Lymphocytes;biomarker identification;Blood - brain barrier anatomy;Brain;Breast Cancer Cell;Breast Cancer Model;Breast Cancer Patient;CAR T cell therapy;CCL2 gene;CD19 gene;CD276 gene;Cell Physiology;Cells;cellular engineering;Characteristics;checkpoint therapy;chemokine;chemokine receptor;chemotherapy;chimeric antigen receptor;chimeric antigen receptor T cells;Chondroitin Sulfate Proteoglycan;Clinical;Clinical Data;Clinical Research;Clinical Trials;comparison control;Correlative Study;Data;design;Endocrine;Engineering;Engraftment;ERBB2 gene;experience;Family;Future;Gene Amplification;Glioblastoma;Hematologic Neoplasms;Heterogeneity;Immune;Immune checkpoint inhibitor;Immune Targeting;Immuno-Chemotherapy;Immunocompetent;Immunotherapy;improved;In Vitro;in vivo;inhibitor therapy;Integral Membrane Protein;Investigation;Lung Neoplasms;Malignant Breast Neoplasm;Malignant lymphoid neoplasm;Malignant neoplasm of ovary;Memory;Metastatic malignant neoplasm to brain;Metastatic Neoplasm to the Lung;Modeling;Modification;mouse model;Mus;neoplastic cell;next generation;Normal tissue morphology;novel;novel strategies;novel therapeutics;Outcome;overexpression;Pathway interactions;Patients;Pharmaceutical Preparations;Phase;phase 1 study;Phase I Clinical Trials;Play;pre-clinical;Pre-Clinical Model;prevent;Prognosis;receptor;Reporting;Resistance;response;safety assessment;safety testing;Signal Transduction;Solid Neoplasm;stem cells;STING agonists;success;T cell therapy;T-Lymphocyte;targeted treatment;Testing;Toxic effect;trafficking;translational potential;triple-negative invasive breast carcinoma;tumor;Tumor Escape;tumor microenvironment;Xenograft Model;Xenograft procedure


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Breast Cancer;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Data Science;Genetics;Human Genome;Networking and Information Technology R&D (NITRD);Precision Medicine;Women's Health Research

PI_NAMEs: HOADLEY, KATHERINE A. (contact)

PROJECT_TERMS: analysis pipeline;anti-cancer research;Bioinformatics;Bioinformatics Shared Resource;biomarker discovery;Biometry;Biostatistics Core;Biostatistics Shared Resource;cancer clinical trial;career;clinical decision-making;Clinical Protocols;Clinical Research;Clinical Trials Design;cluster computing;Collaborations;complex data;Comprehensive Cancer Center;computer cluster;computer infrastructure;Custom;Data;Data Analyses;data integration;data management;data platform;Data Set;Data Storage and Retrieval;Development;Doctor of Philosophy;Ensure;Environment;experience;Faculty;Future;Genetic;Genetic Transcription;Genome Data Analysis Network;Genomic approach;genomic data;Genomics;Gills;Goals;Grant;high dimensionality;High Performance Computing;Human Resources;Image;Image Analysis;Individual;Informatics;innovation;Leadership;Legal patent;Malignant Breast Neoplasm;Manuscripts;member;method development;Methodology;Mission;next generation sequencing;patient subsets;precision oncology;Preparation;Production;Program Research Project Grants;programs;Public Health Schools;Publications;Research;Research Activity;research and development;Research Design;Research Personnel;Resource Sharing;Resources;RNA Sequences;Sample Size;Sampling;Services;single cell sequencing;skills;Statistical Methods;Technology;The Cancer Genome Atlas;Translational Research;UNC Lineberger Comprehensive Cancer Center;Update

PROJECT_TITLE: Core B: Biostatistics & Bioinformatics


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Human Genome;Immunotherapy;Women's Health Research

PI_NAMEs: CALHOUN, BENJAMIN CARLISLE (contact)

PROJECT_TERMS: Aftercare;Anatomy;anti-cancer research;assay development;Basic Science;Biological;Biological Assay;Biological Specimen Banks;Biopsy;Blood;Breast;Breast Cancer Model;Breast Cancer Patient;breast pathology;cancer epidemiology;Cancer Model;CAR T cell therapy;CD276 gene;Cell Separation;Cells;Cellular Assay;Clinical;Clinical Research;Clinical Sciences;Clinical Trials;Collaborations;Collection;Comprehensive Cancer Center;Cytometry;Development;digital;digital imaging;Doctor of Philosophy;Evaluation;Faculty;Flow Cytometry;Fluorescent in Situ Hybridization;Formalin;Freezing;Fresh Tissue;Genetic;Genetic Engineering;Genomics;Hematoxylin and Eosin Staining Method;Hospitals;Human;human tissue;Image;Image Analysis;imager;Immune;Immunobiology;Immunocompetent;Immunofluorescence Immunologic;Immunogenetics;Immunohistochemistry;Immunologic Monitoring;Immunologics;Immunology;In Situ Hybridization;interest;Laboratories;Leadership;Malignant Breast Neoplasm;Malignant Neoplasms;Medical;medical schools;Medicine;Microbiology;Molecular;Morphology;mouse model;North Carolina;Operative Surgical Procedures;Organoids;Paraffin Embedding;Participant;Pathologist;Pathology;patient derived xenograft model;Population Sciences;Procedures;Process;Protocols documentation;Research;Research Personnel;Resource Sharing;response;Sampling;Scientist;Services;single cell sequencing;Site;Slide;Specimen;Specimen Handling;success;Technical Expertise;Tissue Banks;Tissue Microarray;tissue preparation;Tissue Procurements;Tissues;Training;transcriptome sequencing;transcriptomics;translational genomics;Translational Research;triple-negative invasive breast carcinoma;tumor;tumor microenvironment;Tumor Tissue;tumor-immune system interactions;whole slide imaging

PROJECT_TITLE: Core C: Pathology and Immunobiology Core


NIH_SPENDING_CATS: Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Women's Health Research

PI_NAMEs: EARP, H. SHELTON (contact)

PROJECT_TERMS: Administrator;Advocate;Agriculture;anti-cancer research;Applications Grants;Award;Biomedical Engineering;Breast;Budgets;Cancer Center;Cell Therapy;Clinical;Collaborations;Communities;community engagement;Community Outreach;comparative;Compensation;Data;Databases;Development;Evaluation;Evolution;experience;Extramural Activities;Faculty;Funding;Grant;Historically Black Colleges and Universities;improved;Incidence;Individual;Infrastructure;Institution;instrumentation;Investments;Joints;Lead;Leadership;Malignant Breast Neoplasm;medical schools;Medicine;Mind;Mission;Monitor;Morbidity - disease rate;mortality;novel;patient oriented;Patients;Peer Review;Phase;Pilot Projects;Population;Privatization;Process;programs;Publications;Publishing;recruit;Research;research and development;research faculty;Research Personnel;Research Project Grants;Schools;Sister;Source;System;Technology;technology development;Universities;Work

PROJECT_TITLE: Developmental Research Program


PI_NAMEs: CAREY, LISA A (contact)

PROJECT_TERMS: Academia;Acceleration;Advertisements;anti-cancer research;Attention;Award;Basic Science;Bioinformatics;Biometry;Breast;Cancer Center;candidate identification;career;career development;Clinical;Clinical Research;Clinical Trials;Creativeness;Dedications;design;Discipline;Evaluation;Faculty;Foundations;Funding;graduate student;Grant;Incidence;Infrastructure;Institution;interest;Journals;Leadership;Malignant Breast Neoplasm;Malignant Neoplasms;medical schools;Medicine;Mentors;Mentorship;Monitor;mortality;North Carolina;Participant;Population Research;Positioning Attribute;Postdoctoral Fellow;Principal Investigator;Procedures;Process;Productivity;professor;programs;Publications;Publishing;Qualifying;recruit;Research;Research Personnel;Rest;senior faculty;Sister;Specific qualifier value;Spottings;success;Talents;Time;Training;Training Programs;translational cancer research;Translational Research;translational scientist;Universities;web site;Woman;women faculty;young woman

PROJECT_TITLE: Career Enhancement Program


ORG_CITY: MADISON

ORG_DEPT: MICROBIOLOGY/IMMUN/VIROLOGY

ORG_NAME: UNIVERSITY OF WISCONSIN-MADISON

ORG_STATE: WI

PHR: 8. Project Narrative Diseases caused by protozoan and helminth parasites and arthropod-vectored infectious diseases continue to affect millions of people in resource-poor developing countries. The goal of the Parasitology and Vector Biology training program is to recruit and train the next generation of investigators whose focus is on understanding the basic mechanisms regulating host-parasite interactions as well as animal and human parasite transmission. These future parasitology and vector biology research leaders will contribute to global efforts to control these devastating diseases.

PI_NAMEs: BARTHOLOMAY, LYRIC COLLEEN;KNOLL, LAURA J (contact)

PROGRAM_OFFICER_NAME: SASTALLA, INKA I

PROJECT_TITLE: Parasitology and Vector Biology Training Program

STUDY_SECTION: MID

STUDY_SECTION_NAME: Microbiology and Infectious Diseases Research Study Section[MID]


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Social Determinants of Health

PHR: PROJECT NARRATIVE Black Americans and other underrepresented groups (URGs) face a disproportionate cancer burden, yet racial and ethnic diversity in the biomedical workforce lags behind, including cancer research. The Cancer Undergraduate Research Education Program (CUREP) offers a distinctive ten-week program with hands-on cancer research, professional development, and year-long academic coaching to underrepresented students from a predominantly White university and two Historically Black Colleges and Universities (HBCUs), aiming to prepare them for careers in biomedical cancer research. Ultimately, CUREP's long-term goal is to enhance URGs' participation, representation, and impact in cancer research, thus significantly contributing to expanding diversity in the biomedical workforce.

PI_NAMEs: BRYANT, ASHLEY LEAK;KEKU, TEMITOPE O. (contact);RORIE, CHECO JAMES

PROGRAM_OFFICER_NAME: RADAEV, SERGEY

PROJECT_TERMS: Address;Admission activity;Affect;aluminum sulfate;anti-cancer research;Bachelor's Degree;Basic Science;Biomedical Research;Black American;Black Populations;Black race;Cancer Biology;Cancer Burden;cancer health disparity;cancer prevention;career;Career Choice;career development;Collaborations;college;Communication;Communities;Comprehensive Cancer Center;Degree Completion;design;Development;disadvantaged background;Disparity;disparity elimination;economic disparity;Economically Deprived Population;Education;education research;Elements;Ethics;ethnic diversity;experience;Face;faculty mentor;falls;Family;First Generation College Students;Foundations;Funding;Future;Goals;Graduate Education;graduate student;Grant;Historically Black Colleges and Universities;holistic approach;improved;Individual;Inequality;innovation;interest;Intervention;Knowledge;Laboratories;Life;Low income;Malignant Neoplasms;Mentors;Mentorship;next generation;North Carolina;Outcome;Participant;Personal Satisfaction;Physicians;Population;Population Sciences;Postdoctoral Fellow;Principal Investigator;programs;Public Health;racial diversity;Research;Research Personnel;Resources;role model;Schools;Science, Technology, Engineering and Mathematics;Scientist;Self Efficacy;skills;social;social disparities;STEM career;Structure;Students;Study Skills;success;summer internship;summer program;summer research;Supervision;Time Management;Training;translational cancer research;undergraduate research;undergraduate research experience;undergraduate student;Underrepresented Populations;Underrepresented Students;United States National Institutes of Health;Universities;university student;Work;Writing

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Institutional Training and Education Study Section (F)[NCI-F]


ORG_CITY: BOSTON

ORG_DEPT: ADMINISTRATION

ORG_NAME: HARVARD MEDICAL SCHOOL

PHR: PROJECT NARRATIVE: Overall Program Project This Program Project involves a novel research effort with four interrelated Projects pertaining to types of organizations that deliver oncology care to understand features of care integration that are associated with higher-quality care delivery, more equitable care, and better outcomes for individuals with cancer. Defining and assessing how health systems, independent practices, post-acute care and hospice organizations, and specialty pharmacies integrate oncology care for patients with cancer and understanding how integration is associated with key outcomes of cancer treatment will inform policies and practices that can drive improvement in patient outcomes and patient, clinician, and staff experiences.

PI_NAMEs: KEATING, NANCY L (contact);LANDRUM, MARY BETH

PROGRAM_OFFICER_NAME: WEAVER, SALLIE JAYNE

PROJECT_TERMS: Accountability;acute care;Affect;Area;cancer care;cancer therapy;Capital;care coordination;care delivery;care systems;Caring;Case Study;Cause of Death;Cessation of life;Collaborations;Complex;Contracts;Data;Diagnosis;Diffusion;Discipline;economic disparity;Equity;Ethnic Origin;evidence base;experience;Geography;health assessment;health care service organization;health information technology;Health system;Healthcare;Healthcare Systems;hospice environment;Hospitals;improved;Incentives;Individual;Infrastructure;Institute of Medicine (U.S.);Insurance Carriers;integrated care;Investments;Knowledge;Lead;Learning;Malignant Neoplasms;marginalization;marginalized population;Marketing;Measures;medical specialties;member;novel;Oncology;Outcome;Ownership;Patient Care;Patient-Focused Outcomes;Patients;Pattern;payment;Persons;Pharmacy facility;Policies;Population Heterogeneity;practice factors;Price;Probability;Process;programs;Protocols documentation;Quality of Care;Race;Reporting;Research;Research Personnel;Research Project Grants;residence;rural area;Site;socioeconomics;Structure;Subgroup;Surveys;System;Team Process;Time;Underserved Population;Vision;Vulnerable Populations;Writing

PROJECT_TITLE: Understanding Integration in Oncology Care and Association with Quality and Outcomes

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 RPRB-J (M1)]


NIH_SPENDING_CATS: Cancer

PHR: PROJECT NARRATIVE: Administrative Core The Administrative Core will oversee and support the achievement of this Program Project, which seeks to examine care integration across four different types of settings and assess how care integration is associated with better care and outcomes for patients with cancer. The Administrative Core will provide oversight and administrative support and will lead activities related to dissemination of study results to the public, the broader research community, and key stakeholders, including patients, clinicians and clinician leaders, payers, and policymakers.

PI_NAMEs: KEATING, NANCY L (contact)

PROJECT_TERMS: Achievement;Agreement;Caring;Communication;Communities;Complex;Computers;Critiques;Data;Data Collection;Ensure;Equipment;equity, diversity, and inclusion;Evaluation;Goals;Grant;Health Policy;Human Resources;Institutional Review Boards;Lead;Logistics;Maintenance;Malignant Neoplasms;Mediation;medical schools;meetings;Oncology;Outcome;Patient-Focused Outcomes;Patients;Policy Maker;Postdoctoral Fellow;programs;Recording of previous events;recruit;Research;Research Project Grants;Schedule;Statistical Methods;Structure;Students;timeline;Travel;Work


NIH_SPENDING_CATS: Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Rural Health;Social Determinants of Health

PHR: PROJECT NARRATIVE: Project 1 - Care Integration for Patients with Cancer Treated in Health Systems Vertically integrated health systems (i.e., organizations that own and operate both hospitals and medical practices) deliver an increasing proportion of cancer care, but the impact of such integration on patients with cancer remains unclear. This research, together with the other Projects that will use data from Project 1, will seek to characterize how vertical integration relates (if at all) to forms of integration that might have more direct benefits for patient care. By studying care integration in systems caring for patients with cancer, the proposed research will help policymakers and cancer care leaders and clinicians to identify and facilitate care integration that leads to higher quality, more efficient care for patients with cancer.

PI_NAMEs: KERRISSEY, MICHAELA JUNE (contact)

PROJECT_TERMS: Accountability;Acute;Area;cancer care;care coordination;care systems;Caring;Case Study;Characteristics;Clinical;Collaborations;Communities;Complex;Cross-Sectional Studies;Data;Discipline;Equity;Ethnic Origin;Geography;Goals;Health Status;Health system;Healthcare;hospital utilization;Hospitals;improved;Insurance Carriers;Integrated Health Care Systems;Interview;Link;Malignant Neoplasms;marginalization;marginalized population;Marketing;Measures;Medicaid;Medical;Medical Oncologist;medical specialties;Medicare;morphogens;Oncologist;Oncology;Outcome;Ownership;Palliative Care;Patient Care;Patients;Pattern;Performance;Persons;Pharmacy facility;Physicians;Policies;Policy Maker;Process;programs;Protocols documentation;Quality of Care;Race;Radiation Oncologist;Research;Resource-limited setting;Resources;rural residence;Sampling;Site;social deprivation;Specialist;Subgroup;Surgeon;Surveys;System;Time;Unit of Measure;Variant;Vision;Work;Writing

PROJECT_TITLE: Project 1: Care Integration for Patients with Cancer Treated in Health Systems


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Palliative Care;Rural Health;Social Determinants of Health

PHR: PROJECT NARRATIVE: Project 2 – Care Integration for Patients with Cancer Treated in Independent Practices To achieve the best possible outcomes for the large number of cancer patients treated in independent oncology practices, medical oncologists and practice staff must coordinate and integrate care with other clinicians and across a wide range of organizational boundaries and settings and over time. This project will generate new knowledge about the current state of care integration for cancer patients and about how cancer care can be better integrated to improve care for diverse sets of patients. The findings will inform practice leaders and policymakers about changes in organizations, markets, and policies to facilitate care integration that leads to higher quality and more efficient care for patients with cancer.

PROJECT_TERMS: Acceleration;Accountability;Acute;acute care;Area;cancer care;Cancer Patient;care coordination;care delivery;care outcomes;Caring;Case Study;Clinical;Collaborations;Communities;Continuity of Patient Care;COVID-19;Data;density;economic disparity;end of life care;Equity;Ethnic Origin;Evaluation;experience;Goals;Health Status;Health system;hospice environment;Hospitals;improved;Individual;Insurance Carriers;integrated care;Interview;Investigation;Knowledge;Learning;Malignant Neoplasms;marginalization;marginalized population;Marketing;Measurement;Measures;Medicaid;Medical Oncologist;Medical Oncology;medical specialties;Medicare;multidisciplinary;Oncologist;Oncology;Outcome;Ownership;palliative;Palliative Care;Patient Care;Patient-Focused Outcomes;Patients;Pattern;Pharmaceutical Services;Pharmacists;Pharmacy facility;Policies;Policy Maker;pressure;Process;Protocols documentation;Quality of Care;Race;Radiation Oncologist;residence;Resources;Rural;rural area;Sampling;Services;Site;socioeconomics;Specialist;Subgroup;Surgeon;Surveys;survivorship;System;Systemic Therapy;Time;trend;Variant;Vision

PROJECT_TITLE: Project 2: Care Integration for Patients with Cancer Treated in Independent Practices


NIH_SPENDING_CATS: Aging;Behavioral and Social Science;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Palliative Care;Patient Safety;Social Determinants of Health

PHR: PROJECT NARRATIVE: Project 3 – Care Integration for Patients with Cancer Receiving Post- Acute Care and Hospice There has been substantial consolidation in post-acute care (i.e. skilled nursing facilities, inpatient rehabilitation facilities, and home health) and hospice settings, but the impact of such structural integration on patients with cancer remains unclear. This research, together with the other Projects will seek to characterize how structural integration relates (if at all) to other forms of integration that might have more direct benefits for patient care. By studying care integration for patients with cancer treated in post-acute care and hospice settings, the proposed research will help clinicians, cancer care leaders, and policymakers to identify and facilitate more meaningful care integration that leads to higher quality and more equitable care for patients with cancer.

PI_NAMEs: LANDRUM, MARY BETH (contact)

PROJECT_TERMS: Accountability;Acute;acute care;Adverse event;Area;cancer care;Cancer Patient;cancer surgery;care coordination;Caregivers;Caring;Case Study;Clinical;Clinical Skills;Collaborations;Communication;Complex;Computer Systems;Contracts;cost;Data;Disease;economic disparity;Employment;end of life;end of life care;Equity;Ethnic Origin;experience;Family;Geography;Health;Health Status;Health system;Home;Home Care Services;Hospice Care;hospice environment;hospice utilization;hospital readmission;Hospitalization;Hospitals;improved;improved outcome;Incentives;Individual;Inpatients;Insurance Carriers;Intervention;Interview;Malignant Neoplasms;marginalization;marginalized population;Marketing;Measures;Medicaid;Medical;Medicare;Nurse Administrator;Oncology;Outcome;Ownership;Patient Care;Patient-Focused Outcomes;Patients;Pattern;people of color;Policies;Policy Maker;Population;Postoperative Complications;Prevalence;Price;Process;Protocols documentation;Quality of Care;Race;Rehabilitation therapy;Research;residence;Risk Factors;Rural;Sampling;Services;Skilled Nursing Facilities;social;socioeconomics;Subgroup;Surveys;System;Vision

PROJECT_TITLE: Project 3: Care Integration for Patients with Cancer Receiving Post-Acute Care and Hospice


NIH_SPENDING_CATS: Cancer;Clinical Research;Health Services;Social Determinants of Health

PHR: PROJECT NARRATIVE: Project 4 - Care Integration for Patients with Cancer Using Specialty Pharmacies This Project will examine the extent to which pharmacy services are integrated into practices (in the presence and absence of structural integration) and the role of specialty pharmacies in working with oncologists and patients to ensure that patients can access, initiate, and adhere to prescribed oral anticancer medications and supportive care medications. The findings will inform specialty pharmacy leaders, oncology practice leaders, and policy makers about strategies to facilitate care integration to improve care delivery for patients with cancer who may benefit from oral anticancer and supportive care medications.

PROJECT_TERMS: Accountability;Address;Adherence;Adverse effects;anti-cancer;Antineoplastic Agents;Area;beneficiary;cancer care;cancer therapy;care coordination;care systems;Caring;Case Study;Characteristics;Clinical;Collaborations;Complex;Contracts;Data;deprivation;Discipline;Drug Prescriptions;Equity;Ethnic Origin;Financial Support;Geography;Health;Health system;Healthcare Systems;Hospitals;improved;Individual;Infusion procedures;Insurance Carriers;Legal;Malignant Neoplasms;marginalization;marginalized population;Marketing;Measures;Medicaid;Medical;medical specialties;Medicare;medication compliance;Medicine;Oncologist;Oncology;Oral;Oral Administration;Outcome;Ownership;Patient Care;Patient-Focused Outcomes;Patients;Persons;Pharmaceutical Preparations;Pharmaceutical Services;Pharmacists;Pharmacy facility;Policies;Policy Maker;Price;prior authorization;Process;Protocols documentation;Quality of Care;Race;Research;residence;Role;Rural;Site;Subgroup;Supportive care;Surveys;System;Time;treatment adherence;Uninsured Medical Expense;Visit;Work

PROJECT_TITLE: Project 4: Care Integration for Patients with Cancer Using Specialty Pharmacies


PHR: PROJECT NARRATIVE: Statistical Methods and Data Core The. Statistical Core will complement and support the aims of the Projects by providing data management expertise and coordination, coordinating analytic tasks and providing statistical expertise, and developing and applying novel methods for network analyses of health care delivery. The Program Project’s results will inform health care provider organizations and policymakers about the relationship of multiple forms of integration to care for patients with cancer.

PI_NAMEs: HATFIELD, LAURA  (contact)

PROJECT_TERMS: Agreement;archive data;Area;cancer care;care delivery;Caring;Categories;Code;comorbidity;Complement;complex data;Creativeness;Data;Data Linkages;data management;data privacy;Data Set;deprivation;Eligibility Determination;Enrollment;Ensure;Exclusion;experience;Faculty;Geography;Goals;health care delivery;Health Personnel;Individual;Institutional Review Boards;Knowledge;Malignant Neoplasms;Maps;Measurable;Measures;Medicaid;Medicare;member;method development;Methods;Modeling;novel;Oncology;Outcome;Ownership;Pathway Analysis;Patient Care;Patients;Physicians;Policy Maker;Positioning Attribute;Process;programs;Protocols documentation;Provider;Research;Research Methodology;Research Personnel;Sampling;Secure;Security;Site;Specific qualifier value;Standardization;Statistical Methods;Surveys;System;task analysis;Technical Expertise;Time

PROJECT_TITLE: Statistical Methods and Data Core


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Chronic Pain;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurosciences;Pain Research;Social Determinants of Health

ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

PHR: PROJECT NARRATIVE This proposal is designed to establish an interdisciplinary training program in clinical pain research at Mass General Brigham (MGB) in Boston. The long-term goal is to expand the number, diversity, and collaborative network of clinical pain researchers, advancing our understanding of pain and our ability to effectively manage pain without opioid medications. This program offers interdisciplinary mentorship and training in clinical pain research by bringing together a diverse group of mentors from an array of backgrounds, including Psychology, Neurology, Neuroscience, Psychiatry, Epidemiology to promote innovative solutions for pain management and improve patient care by providing high-quality training to future leaders in clinical pain research.

PI_NAMEs: EDWARDS, ROBERT R (contact);SCHREIBER, KRISTIN

PROGRAM_OFFICER_NAME: SYPEK, ELIZABETH IRENE

PROJECT_TERMS: Address;Boston;career;Chronic;clinical pain;Clinical Research;cohort;comorbidity;Dedications;design;Disabled Persons;disadvantaged background;effective intervention;Enrollment;Epidemiology;Ethnic Population;experience;Foundations;Funding;Future;Goals;health equity;improved;Individual;innovation;Learning;life span;Mentors;Mentorship;Neurology;Neurosciences;next generation;non-opioid analgesic;Nonpharmacologic Therapy;Pain;pain chronification;Pain management;Pain Research;Patient Care;peer coaching;Pharmacological Treatment;Positioning Attribute;Postdoctoral Fellow;prevent;Process;programs;Psychiatry;Psychology;racial population;Records;recruit;Research;Research Personnel;Research Training;responsible research conduct;social health determinants;Solid;Time;Training;Training Programs;Universities

PROJECT_TITLE: Mass General Brigham Interdisciplinary Clinical Pain Research Training Program

STUDY_SECTION_NAME: Special Emphasis Panel[ZNS1 SRB-F (90)]


ORG_CITY: STANFORD

ORG_NAME: STANFORD UNIVERSITY

PHR: PROJECT NARRATIVE The COVID-19 pandemic has emphasized that investigations of host-microbe interaction, vaccination, pathogenesis, and host immune responses are critical topics for inquiry in science and medicine. This Training Program takes a holistic approach to train graduate students and postdoctoral fellows in innovative and interdisciplinary approaches to study host-microbial interaction. We combine rigorous courses, mentored laboratory-based research, and an array of training activities all within a Program focused on fostering diversity and the highest standards of ethics and research conduct.

PI_NAMEs: SONNENBURG, JUSTIN L (contact)

PROJECT_TERMS: Molecular;Parasites

PROJECT_TITLE: Molecular Basis of Host Parasite Interaction

STUDY_SECTION_NAME: Microbiology and Infectious Diseases B Research Study Section[MID-B]


ORG_CITY: SEATTLE

ORG_NAME: FRED HUTCHINSON CANCER CENTER

ORG_STATE: WA

PHR: Project Narrative Overall The goal of this Program Project Grant is to develop improved, curative therapies for patients with hematological malignancies focusing primarily on adoptive cell therapy, including hematopoietic cell transplantation. Individual Projects will explore the mechanisms of immune escape after adoptive T cell therapy in preclinical systems and rational design of innovative approaches to improve the targeting of tumors by engineered T cells. Clinical studies will analyze the parameters of CAR T cell success and failure in multiple myeloma and study next generation transgenic T cells targeting WT1 to prevent relapse of acute leukemia.

PI_NAMEs: HILL, GEOFFREY ROGER (contact)

PROGRAM_OFFICER_NAME: HENDERSON, LORI A

PROJECT_TERMS: Acute Graft Versus Host Disease;Acute leukemia;Acute Lymphocytic Leukemia;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Adoptive Cell Transfers;Adult;adult leukemia;Affinity;Age Years;Allogenic;Antigens;Autologous;Autologous Stem Cell Transplantation;Biometry;Bone Marrow;Bone Marrow Transplantation;CAR T cell therapy;Categories;CD19 gene;CD8-Positive T-Lymphocytes;Cell Physiology;Cell Therapy;Cells;Cellular immunotherapy;chimeric antigen receptor;chimeric antigen receptor T cells;chronic graft versus host disease;Clinical;Clinical Research;curative treatments;Cyclophosphamide;cytokine;cytokine release syndrome;data management;design;dimensional analysis;Disease;disorder prevention;Effectiveness;Elderly;engineered T cells;Engineering;Failure;Generations;genetically modified cells;Goals;graft failure;graft vs host disease;graft vs leukemia effect;Grant;Hematologic Neoplasms;Hematopoietic Stem Cell Transplantation;Hemophagocytic Lymphohistiocytoses;high dimensionality;high risk;Immune;Immunity;Immunologic Factors;Immunologics;improved;improved outcome;Incidence;Individual;Infection;Infection prevention;Infusion procedures;innovation;Learning;Lentivirus Vector;leukemia;leukemia relapse;leukemia treatment;Longterm Follow-up;Lymphoma;Malignant Neoplasms;Memory;Minor Histocompatibility Antigens;Modeling;Modernization;Morbidity - disease rate;mortality;Multiple Myeloma;Natural Killer Cells;Neoadjuvant Therapy;Neurotoxicity Syndromes;next generation;novel;novel strategies;Opportunistic Infections;Outcome;pathogen;Patient-Focused Outcomes;Patients;Phase;Phase I/II Trial;Phenotype;post-transplant;pre-clinical;preclinical study;prevent;Prevention;Probability;Program Research Project Grants;programs;Progression-Free Survivals;Proteins;Quality of life;rational design;receptor;receptor function;Recurrent disease;Refractory;Relapse;relapse prevention;Research;Resources;response;Safety;safety assessment;Sampling;Sensitivity and Specificity;Signal Transduction;stem;stem cells;success;System;T cell differentiation;T cell therapy;T memory cell;T-Cell Receptor;T-Lymphocyte;Testing;Therapeutic immunosuppression;Toxic effect;transplant survivor;Transplantation;Treatment Failure;tumor;Tumor Antigens;Work;WT1 gene

PROJECT_TITLE: Adult Leukemia Research Center

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 RPRB-L (M1)]


NIH_SPENDING_CATS: Cancer;Hematology;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

PHR: PROJECT NARRATIVE By providing centralized essential administrative support and budgetary oversight, this Core assists all Projects and Cores on this Program Project Grant in achieving their overall goal of developing improved therapies for patients with hematological malignancies, focusing primarily on adoptive cell therapy and hematopoietic cell transplantation.

PROJECT_TERMS: Adoptive Cell Transfers;adult leukemia;Area;Communication;Goals;Hematologic Neoplasms;Hematopoietic Stem Cell Transplantation;human subject;IACUC;improved;Institution;Institutional Review Boards;Manuscripts;meetings;Occupational activity of managing finances;Patients;Preparation;Program Research Project Grants;Program Reviews;programs;Regulation;Research;Research Personnel;Research Project Grants;Services;United States National Institutes of Health;Vertebrates

PROJECT_TITLE: Core A: Administration


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Gene Therapy;Genetics;Hematology;Immunotherapy;Infectious Diseases;Orphan Drug;Pediatric;Pediatric Cancer;Prevention;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human;Transplantation

PHR: Narrative Disease relapse, graft-versus-host disease (GVHD)/cytokine release syndrome (CRS) and opportunistic infection are the major limitations of adoptive cell therapy (ACT), be it hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) or T cell receptor (TCR) transgenic T cell therapy. We plan to utilize unique, but well-established preclinical models to define the impact of these new clinical HCT platforms on the cellular and molecular pathways that mediate pathogen and leukemia specific immune responses. We will expand these studies to new fully murine CAR T cell models of B cell leukemia and multiple myeloma, focussing on identification of pathways of both toxicity and immune escape. In this manner we will facilitate the development of a new generation of cell therapies that will optimize patient outcomes within this P01.

PROJECT_TERMS: Acute Lymphocytic Leukemia;Adoptive Cell Transfers;adult leukemia;Alloantigen;Allogeneic Bone Marrow Transplantation;Allogenic;antigen-specific T cells;Antigens;antitumor effect;Antitumor Response;B-Cell Leukemia;bcr-abl Fusion Proteins;Bone Marrow;Bone Marrow Transplantation;Calcineurin inhibitor;CAR T cell therapy;CD19 gene;Cell model;Cell Physiology;Cell Therapy;Cells;chimeric antigen receptor;chimeric antigen receptor T cells;Clinic;Clinical;Complication;curative treatments;Cyclophosphamide;Cyclosporins;cytokine;Cytokine Receptors;cytokine release syndrome;Cytomegalovirus;Cytomegalovirus Infections;Development;engineered T cells;exhaustion;Flow Cytometry;FOXP3 gene;Frequencies;Functional disorder;Generations;Genes;Genetic;graft vs host disease;graft vs leukemia effect;Hematopoietic Neoplasms;Hematopoietic Stem Cell Transplantation;HOXA9 gene;Human;Immune;Immune response;Immunity;Immunologics;Immunosuppression;Immunotherapy;improved;Inflammation;innovation;Interferons;Interleukin-10;interleukin-12 receptor;leukemia;leukemia/lymphoma;Life;Malignant Childhood Neoplasm;Malignant Neoplasms;Mediating;Memory;MLL-AF9;Modeling;Modernization;Molecular;mortality;Multiple Myeloma;multiple omics;Murid herpesvirus 1;Mus;Natural Killer Cells;Nature;novel;novel therapeutic intervention;Opportunistic Infections;Outcome;pathogen;Pathway interactions;Patient-Focused Outcomes;Patients;Phenotype;Population;post-transplant;pre-clinical;Pre-Clinical Model;preclinical study;prevent;Prevention strategy;Prophylactic treatment;receptor;Receptor Cell;Recurrent disease;Relapse;Reporter;Reporting;Research;Residual state;Resistance;response;spectrograph;stem;stem cells;System;T cell differentiation;T cell response;T cell therapy;T memory cell;T-Cell Depletion;T-Cell Receptor;T-Lymphocyte;Testing;Therapeutic;Toxic effect;Transcript;Translating;transplant model;Transplantation;tumor;Tumor Antigens;Tumor Immunity

PROJECT_TITLE: Defining the Mechanisms of Immune Escape After Adoptive T cell Therapies


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Clinical Research;Gene Therapy;Genetics;Hematology;Immunotherapy;Orphan Drug;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Stem Cell Research - Nonembryonic - Non-Human

PHR: PROJECT NARRATIVE Multiple myeloma is diagnosed in 35000 Americans each year. New drugs and chimeric antigen receptor modified T cells (CAR-T) have improved response rates for myeloma and prolonged survival for many patients, but most patients eventually die of disease progression. This project will develop new tumor targeting receptors and methods for adoptive T cell therapies to overcome mechanisms by which myeloma cells resist eradication.

PI_NAMEs: RIDDELL, STANLEY R. (contact)

PROJECT_TERMS: Acceleration;Adoptive Cell Transfers;Adoptive Transfer;adult leukemia;Aftercare;American;Antigen Targeting;Antigens;Architecture;Autologous;Autologous Stem Cell Transplantation;Binding;Biological Products;blood resource;Bone Marrow;Bone Marrow Neoplasms;cancer therapy;CAR T cell therapy;Cell Physiology;Cell surface;Cells;chimeric antigen receptor;chimeric antigen receptor T cells;clinical translation;curative treatments;Cytogenetics;Data;density;design;Development;Diagnosis;dimensional analysis;Disease;Disease Progression;Disease remission;engineered T cells;Engineering;Epigenetic Process;Extramedullary;Functional disorder;gamma secretase;Gene Transfer;Generations;Genetic Transcription;genetically modified cells;Hematopoietic Stem Cell Transplantation;Heterogeneity;high dimensionality;high risk;Human;Hybrids;immune modulating agents;Immunity;Immunologic Techniques;Immunotherapy;Impairment;improved;In complete remission;In Vitro;in vivo;Infusion procedures;inhibitor;insight;International;Ligands;Maintenance;Mediating;Memory;Methods;Monoclonal Antibodies;mouse model;Multiple Myeloma;Mus;neoplastic cell;novel;novel strategies;novel therapeutics;Oral Administration;Outcome;Patients;Pharmaceutical Preparations;Pharmacotherapy;phase I trial;Phenotype;Pre-Clinical Model;prevent;Prior Therapy;Progression-Free Survivals;Proteasome Inhibitor;receptor;Receptor Signaling;Recurrent disease;Refractory;Refractory Disease;Relapse;Research;Resistance development;resistance mechanism;response;Sampling;secretase;Signal Transduction;Specificity;Staging System;stem cells;stemness;Surface;synthetic biology;T cell therapy;T-Cell Activation;T-Cell Receptor;T-Lymphocyte;targeted treatment;Techniques;Testing;Therapeutic;therapy resistant;Time;TNFRSF17 gene;Treatment Efficacy;Treatment Failure;tumor;Tumor Burden;Tumor Escape;tumor microenvironment;Work

PROJECT_TITLE: Engineering Effective T cell Immunity to Multiple Myeloma